Lung Cancer ScreeningLUCAS-LATAMNCT07524803
Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America(LUCAS-LATAM)
An observational study of Lung Cancer Screening, run by Latin American Consortium for the Lung Cancer Research at 2 sites in 2 countries.
Trial summary
Prospective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in patients with other high risk criteria… Read more about this study
- Who is it for?
- Ages 50 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer Screening
- What is being tested?
- Chest X-Ray, Low Dose CT scan
- How many people
- 2,000 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 1 May 2026to 1 May 2032
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 2000 patients will be recruited in 4 Latin American countries (Mexico 700 pts,Costa Rica 300 pts, Colombia 500 pts, Argentina 500 pts)
Who may be able to join
- 1. Men and women ≥50 years of age and one of any of the following criteria:
- Exposure to wood smoke (at least 100 hours per year)
- A family history of lung cancer in first-degree relatives
- A diagnosis of COPD and/or emphysema
- Smokers with a tobacco index of 10 years or more
Who cannot join
- Lung cancer diagnosis or any other type of active cancer during the 5 years prior to the screening
- Incomplete clinical information
- Loss of 10% of the baseline weight during 6 months prior to study entry
- Having a functional status, psychiatric condition or comorbidity that precludes curative treatment
- Any situation that makes the subject ineligible for LDCT
- Life expectancy ≤5 years
- Subjects with previous history of pulmonary nodules.
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
Costa Rica1 site
Centro de Investigacion y Manejo del Cancer (CIMCA)
San José, Provincia de San José, 10103
Luis Corrales, +506 40202222, corrales@cimcacr.com
About this study
Official title: A Prospective Observational Study to Determine the Utility of Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America
Prospective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in patients with other high risk criteria to develop lung cancer. 2000 patients will be recruited in 4 LATAM countries (Mexico 700 pts, Costa Rica 300 pts, Colombia 500 pts, Argentina 500 pts). All patients will be ≥50years of age with one of the following additional inclusion criteria: a. exposure to wood smoke (at least 100 hours/year), b.family history of lung cancer in a first degree relative, c. COPD and/or emphysema, d. smokers with a tobacco index of 10 y or more. The exclusion criteria include: a. lung cancer diagnosis or other type of cancer 5 years prior to screening, b. loss of 10% of baseline weight 6 months before inclusion, c. ineligible for LDCT, d. life expectancy ≤5 years, and e. previous history of pulmonary nodules.
The primary objective of the study is the utility of LDCT-based lung cancer screening in identifying suspicious lung nodules in smokers and non-smokers across LATAM, with secondary objectives including: 1- Utility of qXR-LNMS (lung nodule malignancy score) of chest XRay for lung cancer risk assessment to exclude low risk patients from LDCT screening, 2- Utility of LDCT-based lung cancer screening in subjects with various risk profiles in LATAM, 3- Prevalence of lung nodules in the study population, 4-Mortality rate in the subjects diagnosed with an anomaly in the LDCT (with or without LC diagnosis).
- Conditions
- Lung Cancer Screening
- Being tested
- Chest X-Ray, Low Dose CT scan
- Keywords
- lung cancer, screening, low dose CT scan, lung nodule
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Chest X-Ray, Low Dose CT scanDiagnostic test
Visit 1: chest XRay analyzed by qXR (QURE ai) and LDCT1
Visit 2: LDCT2 : (12/24 months as applicable ± 2 weeks)(interval of LDCT2 is determined by the findings of the Visit 1)
- Low risk by qXR and Lung RADS 1 or 2: repeat in 24 months
- Low risk by qXR and Lung RADS 3, high risk by qXR and Lung RADS 1, 2, 3: repeat in 12 months
Telephonic follow-up visits (at 6 month interval post LDCT2 for 2 years)
Any Lung RADS 0, 4A, 4B, 4X or S will be assed in a thoracic oncology multidisciplinary team
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | 2000 patients in 4 LATAM countries, ≥50years of age with one of the following: a. exposure to wood smoke (at least 100 hours/year), b.family history of LC in a first degree relative, c. COPD and/or emphysema, d. smokers with a tobacco index of 10 y or more. Patients will have the following interventios and follow-up: A- Visit 1: chest XRay analyzed by qXR and a LDCT1 B- Visit 2: LDCT2 : (12/24 months as applicable ± 2 weeks)(interval of LDCT2 is determined by the findings of the Visit 1)
1. Low risk by qXR and Lung RADS 1 or 2: repeat in 24 months
2. Low risk by qXR and Lung RADS 3, high risk by qXR and Lung RADS 1, 2, 3: repeat in 12 months C- Telephonic follow-up visits (at 6 month interval post LDCT2 for 2 years) Any Lung RADS 0, 4A, 4B, 4X or S will be assed in a thoracic oncology multidisciplinary team Receives: Diagnostic Test: Chest X-Ray, Low Dose CT scan |
What is being measured
The primary outcome is the main question the study is designed to answer.
Utility of LDCT-based lung cancer screening in identifying suspicious lung nodules in smokers and non-smokers across LATAM
Measured: From enrollment until 5 years of follow-up
Secondary outcomes (4)
Utility of qXR-LNMS of CXR for lung cancer risk assessment to exclude low risk patients from LDCT screening
Measured: From enrollment until 5 years of follow-up
Utility of LDCT-based LC screening in subjects with various risk profiles in LATAM
Measured: From enrollment until 5 years of follow-up
Prevalence of lung nodules in the study population
Measured: From enrollment until 5 years of follow-up
Mortality rate in subjects diagnosed with an anomaly in the LDCT (with or without LC diagnosis)
Measured: From enrollment until 5 years of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start1 May 2026 (estimated)
- Primary completion1 May 2030 (estimated)
- Study completion1 May 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Lung Cancer ScreeningStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Latin American Consortium for the Lung Cancer Research
- Sponsor type
- University, hospital or other
- Collaborators
- Centro de Investigacion y Manejo del Cancer (CIMCA), Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo, Instituto Nacional de Cancerologia de Mexico, Alexander Fleming Institute
- Responsible party
- Sponsor
- Investigators
- Luis Corrales, MD, Principal investigator, Consorcio Latinoamericano para la Investigacion en Cancer de Pulmon (CLICAP)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07524803
- Sponsor's protocol ID
- CLICAP-001
- Acronym
- LUCAS-LATAM
- Status last verified
- Apr 2026
- First submitted
- 6 Apr 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, Mitsuishi Y, Ha G, Campbell JD, Oxnard GR, Arrieta O, Cardona AF, Gusev A, Meyerson M. Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Cancer Discov. 2021 Mar;11(3):591-598. doi: 10.1158/2159-8290.CD-20-1165. Epub 2020 Dec 2.
PubMed 33268447Corrales L, Rosell R, Cardona AF, Martin C, Zatarain-Barron ZL, Arrieta O. Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. Crit Rev Oncol Hematol. 2020 Apr;148:102895. doi: 10.1016/j.critrevonc.2020.102895. Epub 2020 Jan 31.
PubMed 32062313Arrieta O, Zatarain-Barron ZL, Cardona AF, Corrales L, Martin C, Cuello M. Uniting Latin America Through Research: How Regional Research Can Strengthen Local Policies, Networking, and Outcomes for Patients With Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-7. doi: 10.1200/EDBK_349951.
PubMed 35503985Cardona AF, Sanchez N, Gutierrez-Babativa L, Rojas L, Zuluaga J, Martinez S, Viola L, Carvajal C, Bogoya J, Prieto-Pinto L, Samaca-Samaca D, Robles A, Kock J, Martin C, Corrales L, Raez LE, Cordeiro de Lima V, Samtani S, Arrieta O. Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study. Lancet Reg Health Am. 2025 Jul 2;49:101172. doi: 10.1016/j.lana.2025.101172. eCollection 2025 Sep.
PubMed 40688567Lam S, Bai C, Baldwin DR, Chen Y, Connolly C, de Koning H, Heuvelmans MA, Hu P, Kazerooni EA, Lancaster HL, Langs G, McWilliams A, Osarogiagbon RU, Oudkerk M, Peters M, Robbins HA, Sahar L, Smith RA, Triphuridet N, Field J. Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2024 Jan;19(1):36-51. doi: 10.1016/j.jtho.2023.07.019. Epub 2023 Jul 23.
PubMed 37487906